HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership (PRNewswire) - Jul 8, 2026 - "Under the MOU, the two companies will conduct preclinical and translational research evaluating HCB101 in combination with InxMed's investigational assets, including IN10018/ifebemtinib, a FAK inhibitor, and OMTX705....HanchorBio has been developing the asset with gastric cancer as an important clinical anchor....InxMed brings a complementary profile. Its lead asset, IN10018/ifebemtinib, has advanced into late-stage clinical development, including a Phase III trial in China for platinum-resistant recurrent ovarian cancer....The collaboration gives HanchorBio a way to test whether HCB101's macrophage-centered immune activation can be paired with drugs targeting the tumor's physical and biological defenses, including fibrosis, stromal barriers, and immune exclusion."
Licensing / partnership • Platinum resistant • Gastric Cancer • Ovarian Cancer
|